HHLA2:在内分泌相关癌症中是一种潜在的生物标志物和治疗标
Christiane Gruetzmacher1, Bruna Sousa Pessoa1, Flora Ladeira Craveiro1
1Neuroendocrinology Unit, Division of Endocrinology and Metabolism, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Endocrine oncology (Bristol, England)
|April 21, 2025
概括
人体内源性逆转录病毒-H长终端重复关联2 (HHLA2) 在内分泌癌症中发挥了多种作用. 这种免疫检查点目标可以作为预后生物标志物,其表达会影响患者的结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 人体内源性逆转录病毒-H长终端重复关联2 (HHLA2),B7家族成员,在各种人类癌症中表达.
- HHLA2被认为是癌症治疗的潜在免疫检查点标.
- 它在内分泌相关癌症中的作用需要进一步阐明.
研究的目的:
- 整合现有的关于内分泌相关癌症中HHLA2表达的数据.
- 评估HHLA2作为这些癌症的预后生物标志物.
- 了解HHLA2在瘤微环境中的双重功能.
主要方法:
- 在PubMed,Web of Science和Embase的系统文献搜索到2024年12月.
- 纳入标准侧重于对内分泌相关癌症中HHLA2的研究.
- 搜索术语包括"HHLA2"",B7-H7"",B7y"",B7-H5"和相关的癌症类型.
主要成果:
- 在被审查的117项研究中,有12项研究符合纳入标准.
- 胰腺癌:HHLA2表达变化,高水平与更好的预后有关.
- 卵巢癌:关于HHLA2和生存的结果相互矛盾;甲状腺癌和神经内分泌瘤:HHLA2与预后不佳和转移有关.
结论:
- 在内分泌相关的瘤中,HHLA2表现出双重作用 (免疫抑制和瘤抑制).
- 瘤微环境可能会影响HHLA2的表达.
- 作为免疫检查点生物标志物和瘤学中的治疗点,HHLA2显示出前景.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.6K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.4K
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:38Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K